Ranbaxy receives final approval for simvastatin in Canada
This article was originally published in Scrip
Ranbaxy Laboratories has received final approval from Health Canada's Therapeutic Products Directorate to manufacture and market the lipid metabolism regulator, Ran-Simvastatin 5mg, 10mg, 20mg, 40mg and 80mg tablets (simvastatin), there. The company expects to launch Ran-Simvastatin in September at an affordable price that would benefit the Canadian healthcare system and patients. The generic market for simvastatin tablets in Canada is estimated at Cdn$153 million ($138.2 million).
You may also be interested in...
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.